MedTrace Logo

Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)

NCT01075711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2728

Last updated 2014-02-19

No results posted yet for this study

Summary

Rheumatoid arthritis is the most common rheumatic disease with symptomatic morning stiffness which entails a quite essential restriction in the everyday life and in the life quality. This observational, uncontrolled, multicentric study is aimed to assess the improvement in the activity status or QoL of subjects with RA being treated with the Tempus tablet.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Prednisone

According to SPC

Sponsors & Collaborators

  • Merck Serono GmbH, Germany

    collaborator INDUSTRY

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Dr. Boris Pfeiffer, M.Sc. · Merck Serono GmbH, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-09-30
Completion
2010-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075711 on ClinicalTrials.gov